What actually happens to your body when you stop Ozempic
Quick answer
GLP-1 receptor agonists like semaglutide suppress appetite through central and peripheral mechanisms that reverse after discontinuation, making weight regain common and biologically predictable rather than a behavioral failure. The STEP 1 Extension trial (Wilding et al., 2022) documented two-thirds weight regain within 12 months of stopping semaglutide, consistent with the video's core claim. Patients considering discontinuation should discuss tapering protocols, maintenance strategies, and realistic expectations with their prescribing clinician before stopping.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @bbcnews actually say?
The video combines personal testimony from a user and commentary from what appears to be a clinician. The central claims are that stopping GLP-1 injections causes appetite to return rapidly, sometimes "the next day," that this rebound feels like "an avalanche" or "tsunami," and that the weight regain is so predictable that the speaker believes they will "always find a way to stay on it." One contributor describes eating compulsively within three days of stopping, without conscious awareness. The framing is honest about side effects during treatment, including nausea, hair loss, and poor sleep, but the overall message tilts toward indefinite use as the only practical solution.
Does the science back this up?
The appetite rebound claim is well-supported. Multiple trials confirm that weight regain after stopping semaglutide is significant and relatively fast. The STEP 1 Extension trial (Wilding et al., 2022, Diabetes, Obesity and Metabolism) found that participants regained two-thirds of their lost weight within one year of stopping semaglutide 2.4mg. Appetite-related hormones, including GLP-1 and ghrelin, return toward baseline within weeks of discontinuation. The "tsunami" description is colorful but not scientifically inaccurate. Where the video gets murkier is the implied permanence of the problem. The suggestion that lifestyle changes alone can maintain weight loss after stopping is plausible but harder to deliver in practice than the video makes it sound.
What did they get wrong (or right)?
They got the rebound physiology largely right. The idea that appetite suppression disappears when the drug leaves your system is accurate. GLP-1 receptor agonists work while they are present; they do not retrain your hypothalamus permanently.
What is oversimplified is the "if you implement lifestyle changes, just continue them" framing. This is technically true but sidesteps a key biological reality: semaglutide changes how the brain responds to food cues. Kullmann et al. (2022, Nature Metabolism) showed that semaglutide reduced activity in reward-related brain regions in response to food. When the drug is gone, those neural responses return. Telling someone to "just continue" a calorie deficit after that shift reverses is easier said than done, and the video does not fully acknowledge that.
The hair loss mention is real. Telogen effluvium from rapid weight loss is documented, though it is usually temporary. That detail was accurate and underreported in most GLP-1 content.
What should you actually know?
Weight regain after stopping GLP-1 medications is not a personal failure. It reflects the drug's mechanism. These medications act on receptors in the brain and gut that regulate hunger signals. When you stop, those signals return. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed that participants who stopped tirzepatide after 36 weeks regained most of their lost weight within the following year, while those who continued lost further weight. This is consistent across the drug class.
- Stopping abruptly versus tapering has not been studied rigorously, so the "three days and then compulsive eating" anecdote is plausible but not universally documented.
- Long-term use is increasingly supported by evidence, but the decision to stay on medication indefinitely should involve a prescribing clinician who knows your full health picture.
- "Addiction" is the wrong word here clinically. Physical dependence on GLP-1 agonists is not established. What the speaker is describing is the return of a pre-existing biological drive, not withdrawal in the pharmacological sense.
Is indefinite use the only answer?
Not necessarily, but it is a legitimate option for many people. The framing that you must stay on these drugs forever to maintain results is gaining clinical traction, largely because the evidence supports it. Obesity is increasingly classified as a chronic, relapsing condition, and treating it intermittently has not worked well historically. That said, "always finding a way to stay on it" is not a clinical recommendation, it is one person's conclusion about their own situation. Individual responses vary, insurance coverage varies, and compounded versions of these drugs are not equivalent to regulated brand-name products. Anyone making this decision should be doing so with a licensed provider, not based on a TikTok video, even a well-intentioned one.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For What actually happens to your body when you stop Ozempic, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
GLP-1 receptor agonists like semaglutide suppress appetite through central and peripheral mechanisms that reverse after discontinuation, making weight regain common and biologically predictable rather than a behavioral failure.
FormBlends verdict
GLP-1 receptor agonists like semaglutide suppress appetite through central and peripheral mechanisms that reverse after discontinuation, making weight regain common and biologically predictable rather than a behavioral failure. The STEP 1 Extension trial (Wilding et al., 2022) documented two-thirds weight regain within 12 months of stopping semaglutide, consistent with the video's core claim. Patients considering discontinuation should discuss tapering protocols, maintenance strategies, and realistic expectations with their prescribing clinician before stopping.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists like semaglutide suppress appetite through central and peripheral mechanisms that reverse after discontinuation, making weight regain common and biologically predictable rather than a behavioral failure. The STEP 1 Extension trial (Wilding et al., 2022) documented two-thirds weight regain within 12 months of stopping semaglutide, consistent with the video's core claim. Patients considering discontinuation should discuss tapering protocols, maintenance strategies, and realistic expectations with their prescribing clinician before stopping.
- The STEP 1 Extension trial (Wilding et al., 2022) found participants regained approximately two-thirds of lost weight within 12 months of stopping semaglutide 2.4mg, making the video's core claim evidence-based.
- Semaglutide has a half-life of roughly 7 days, so appetite return "the next day" is biologically unlikely for most people, though subjective hunger can rise faster as levels begin to fall.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- The STEP 1 Extension trial (Wilding et al., 2022) found participants regained approximately two-thirds of lost weight within 12 months of stopping semaglutide 2.4mg, making the video's core claim evidence-based.
- Semaglutide has a half-life of roughly 7 days, so appetite return "the next day" is biologically unlikely for most people, though subjective hunger can rise faster as levels begin to fall.
- The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed tirzepatide users who discontinued after 36 weeks regained most lost weight within the following year, confirming the pattern holds across the GLP-1 drug class.
- GLP-1 medications are not addictive in the pharmacological sense. Calling ongoing use "addiction" is inaccurate and may discourage people with obesity from pursuing legitimate long-term treatment.
- Kullmann et al. (2022, Nature Metabolism) showed semaglutide reduces activity in brain reward regions in response to food. This effect reverses when the drug stops, which is why behavioral changes alone rarely hold post-discontinuation.
- Hair loss during early treatment is real and documented, typically a telogen effluvium response to rapid weight loss rather than a direct drug effect, and usually resolves on its own.
- Anyone considering stopping or staying on a GLP-1 medication long-term should make that decision with a licensed prescriber. No TikTok video, including this one, is a substitute for individualized clinical guidance.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
BBC News · TikTok creator
4.5M views on this video
Weight-loss injections promise rapid results and have changed lives - but what really happens you quit these jabs? #WeightLoss #WeightLossInjections #Ozempic #Semaglutide #News #BBCNews
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by BBC News, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.